快速连接 发送消息
Tokyo, April 11, 2025 — Dr. Reddy’s Laboratories’ Active Pharmaceutical Ingredients (API) division made a strong impression at CPHI Japan 2025, held at Tokyo Big Sight from April 9–11. As one of the leading global suppliers of high-quality APIs, the company highlighted its expansive portfolio of over 250 APIs across key therapeutic areas including oncology, cardiovascular, and dermatology.
The team, led by Nirav Shah, Vice President and Head of API – North Asia, engaged with partners and stakeholders to discuss sustainable sourcing, regulatory excellence, and early market entry strategies. Dr. Reddy’s also emphasized its commitment to sustainability and ESG leadership, having earned recognition in the Bloomberg Gender-Equality Index and Dow Jones Sustainability Index.
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。
+91 4049002253